-
NLRP10 and Epidermal Barrier Homeostasis in AD
2026-09-22
This Cell Death & Disease study defines NLRP10 as a functional regulator of epidermal homeostasis, linking it to caspase-8-dependent keratinocyte survival, p63 stabilization, differentiation, and barrier integrity. Its human skin evidence and air-lift skin-equivalent model provide a mechanistic framework for studying how NLRP10 deficiency may contribute to atopic dermatitis rather than treating the protein solely as an inflammasome-associated factor.
-
Reparixin: A CXCR1/2 Inhibitor for Mechanism Studies
2026-09-22
Reparixin is a non-competitive allosteric CXCR1/2 inhibitor used to study CXCL8 signaling, neutrophil migration, and inflammatory tissue injury. Its receptor-level activity supports in vitro neutrophil chemotaxis assays and mechanistic studies of acute lung injury research, ischemia-reperfusion injury models, and inflammation research.
-
Stiripentol LDH Inhibitor Workflows
2026-09-21
Use Stiripentol as a direct LDH perturbation tool for dissecting lactate flux, astrocyte-neuron lactate shuttle modulation, and seizure-related metabolism. A reference-backed extension into tumor immunometabolism shows how pairing LDH activity with lactate, histone lactylation, and immune-cell readouts can produce more informative experiments than endpoint lactate measurements alone.
-
Amyloid Beta-Peptide (1-40): Assay Workflow
2026-09-21
Build more reproducible amyloid aggregation, membrane-interaction, and neurotoxicity experiments with a defined human Aβ40 model. This workflow translates calcium-sensitive surface imaging findings into practical controls for aggregation timing, stock handling, and cell-based assay design.
-
Fluconazole at the Host–Fungus Interface
2026-09-20
Fluconazole is a fungal cytochrome P450 enzyme 14α-demethylase inhibitor that disrupts ergosterol biosynthesis and fungal membrane function. Its defined in vitro benchmarks support antifungal susceptibility testing and Candida albicans research, while recent METTL9–PRA1 findings clarify why host nutritional immunity should be measured as a separate biological axis.
-
Tianhuang Formula, Berberine, and RAGE/POMC
2026-09-19
A 2026 pre-proof study identifies RAGE/POMC signaling as a central mechanism through which Tianhuang Formula’s berberine component may improve glucolipid metabolism. By combining network pharmacology, LC-Q/TOF-MS, hypothalamic cell assays, and a high-fat/high-sucrose mouse model, the researchers connect RAGE modulation with neuronal apoptosis, autophagy, glucose tolerance, and triglyceride control.
-
Substrate Stiffness Drives Dentinogenesis via FAK
2026-09-18
Bai and colleagues show that matrix stiffness regulates odontoblast-like cell extension and dentinogenic behavior through a LAMB1–FAK–MEK1/2 signaling axis. The study provides a mechanistic framework for linking cell–material mechanics with reparative dentin formation and offers practical guidance for designing stiffness-controlled dental tissue-engineering experiments.
-
LY2886721: Oral BACE Inhibitor Evidence Guide
2026-09-18
LY2886721 is an oral BACE inhibitor with nanomolar activity in biochemical and cellular assays. Product and peer-reviewed data support its use for amyloid beta reduction studies while showing that exposure level is important for interpreting synaptic effects.
-
Toremifene versus Tamoxifen for Advanced Breast Cancer
2026-09-17
The Cochrane review directly compared two selective estrogen receptor modulators in advanced breast cancer and found no persuasive evidence that toremifene was superior to tamoxifen for tumor response, disease control, progression, or overall survival. Its main contribution is a structured synthesis of head-to-head trial evidence, showing how endpoint selection, trial quality, and adverse-event interpretation should shape conclusions about endocrine therapy.
-
HMGCS2, LysoPC, and Pulmonary Fibrosis
2026-09-17
Yang et al. identify a cell-specific mechanism in which loss of HMGCS2 disrupts lipid degradation in type II alveolar epithelial cells, increasing LysoPC release and activating lung fibroblasts. The study connects epithelial lipid metabolism to fibrosis progression and provides a framework for lipid signaling pathway analysis using defined lysophospholipid perturbations.
-
Amyloid Beta-Peptide (1-40): Research Guide
2026-09-16
Amyloid Beta-Peptide (1-40) (human) is a synthetic 40-residue Aβ40 model for Alzheimer’s disease research. Its defined identity, reported solubility, and storage requirements support controlled amyloid fibril formation study, while calcium-dependent aggregation findings help define experimental limits.
-
Gap19: From Cx43 Biology to Assay Strategy
2026-09-16
Gap19 is a selective connexin 43 hemichannel blocker that connects channel biology with neuroinflammatory assay design. This article interprets macrophage NF-κB findings alongside astrocyte and cerebral ischemia evidence to clarify what the peptide can—and cannot—establish experimentally.
-
LY2886721: Practical BACE Inhibitor Workflows
2026-09-15
LY2886721 supports controlled BACE1 enzyme inhibition across biochemical, neuronal, and translational Alzheimer’s disease research workflows. Its strongest use-case is not simply maximal amyloid beta reduction, but measuring how graded pathway suppression affects APP processing, secreted biomarkers, and synaptic function.
-
Amyloid β-Peptide (1-42) (human): Lab Guide
2026-09-15
A practical, evidence-based guide to using Amyloid β-Peptide (1-42) (human), SKU B6057, in neuronal viability, microglial uptake, and ion-channel experiments. It connects product handling specifications with published Aβ1–42 biology to improve assay interpretation, preparation consistency, and vendor selection.
-
YM 58483 (BTP2) SOCE Research Workflows
2026-09-14
YM 58483 (BTP2) gives researchers a practical way to test whether store-operated Ca2+ entry drives immune activation or fibrosis-associated signaling. This workflow-focused guide covers concentration planning, calcium and NFAT readouts, salivary-gland fibrosis models, and troubleshooting for interpretable SOCE blockade.